Full details, including potential risk factors, are given in the Press Release, which can be consulted by clicking on the link below
A Randomized, Controlled Comparison of NCX 470 (0.021%, 0.042% and 0.065%) and Latanoprost 0.005% in Patients with Open-Angle Glaucoma or Ocular Hypertension: The Dolomites Study

April 11, 2022

View Press Release Corporate presentation Contact us
Previous